



# HHS Public Access

Author manuscript

*J Matern Fetal Neonatal Med.* Author manuscript; available in PMC 2020 September 01.

Published in final edited form as:

*J Matern Fetal Neonatal Med.* 2019 September ; 32(17): 2805–2811. doi:  
10.1080/14767058.2018.1449206.

## ***DEFB1* polymorphisms and HIV-1 Mother-To-Child Transmission in Zambian population**

Luisa Zupin<sup>1</sup>, Vania Polesello<sup>2</sup>, Ludovica Segat<sup>2</sup>, Anselmo Jiro Kamada<sup>3</sup>, Louise Kuhn<sup>4</sup>, and Sergio Crovella<sup>1,2</sup>

<sup>1</sup>Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy

<sup>2</sup>Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy

<sup>3</sup>Department of Genetics, Federal University of Pernambuco, Recife, Brazil

<sup>4</sup>Gertrude H. Sergievsky Center and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA

### **Abstract**

**Introduction.**—Human Beta Defensin-1 (hBD-1) is a component of the innate immune system, the first line of defence against pathogens, already reported as involved in the susceptibility to HIV-1 infection and HIV-1 mother-to-child transmission (MTCT) in different populations.

We investigated the role of *DEFB1* gene (encoding for hBD-1) functional polymorphisms in the susceptibility to HIV-1 MTCT in a population from Zambia.

**Methods.**—Four selected polymorphisms within *DEFB1* gene, three at the 5' untranslated region (UTR), namely –52G>A (rs1799946), –44C>G (rs1800972) and –20G>A (rs11362) and one in the 3'UTR, c.\*87A>G (rs1800972), were genotyped in 101 HIV-1 positive mothers (26 transmitters – 27% and 75 not transmitters – 73%) and 331 infants born to HIV-1 infected mothers (85 HIV-1 positive – 26% and 246 exposed but not infected – 74%).

**Results.**—*DEFB1* c.\*87 A allele was more frequent among HIV- children respect to HIV+ (with intra-uterine MTCT). Concerning *DEFB1* haplotypes, GCGA haplotype resulted more represented in HIV- than HIV+ infants and *DEFB1* ACGG haplotype presented increased frequency in HIV- children respect to HIV+ (with intra-partum MTCT) (p=0.02, p=0.002 and p= 0.006 respectively).

**Conclusion.**—*DEFB1* polymorphisms were significantly associated with decreased risk of HIV-1 infection acquisition in the studied Zambian population suggesting that they may play a role in HIV-1 MTCT.

### **Keywords**

innate immunity; *DEFB1*; HIV-1; polymorphisms; haplotypes

---

Corresponding Author: Dr. Luisa Zupin, Department of Medicine, Surgery and Health Sciences, University of Trieste, Via dell'Istria 65/1, Trieste 34137, Italy, Tel: +39 040 3785422, Fax: +39 040 762623, luisa.zupin@burlo.trieste.it.

Conflict of interest

The authors declared no conflict of interest

## Introduction

Human immunodeficiency type-1 (HIV-1) mother-to-child transmission (MTCT) has been dramatically reduced with the introduction of HIV test in all pregnant women and consequent antiretroviral drugs administration in those positive for virus infection; also alternative to breastfeeding and caesarean partum contributed to prevent MTCT [1]. Nevertheless, data from past years in which antiretroviral drugs were not yet available for prevention provide a unique model to understand the role of host genetic factors in the modulation of HIV-1 infection susceptibility, a multifactorial trait [2].

So far several genes and genetic polymorphisms (e.g. single nucleotide polymorphisms, SNPs) have been described as conferring risk or protection towards HIV-1 infection [3]. Since innate immunity is known to play a crucial role in the immune system of the foetus, we focused our attention on functional genetic variations distributed in primary natural defence genes. Therefore, we studied *DEFB1* (8p23.1) gene encoding for the human beta defensins 1 (hBD-1), an antimicrobial peptide [4], known for its antimicrobial properties against bacteria, fungi but also viruses [5] and already investigated in the context of HIV-1 MTCT [6, 7, 8, 9]. *DEFB1* expression has been detected in the placenta, and a role in the protection against HIV-1 mother-to-foetus transmission has been hypothesized [9].

*DEFB1* gene presents different functional polymorphisms, the  $-52G>A$  (rs1799946),  $-44C>G$  (rs1800972) and  $-20G>A$  (rs11362) at the 5' untranslated region (5'UTR) and c.\*87A>G (rs1800971) at the 3'UTR possibly modulating *DEFB1* gene expression in different cellular models [10, 11, 12, 13].

In this study, taking into account the previously reported role of *DEFB1* genetic variations in the context of HIV-1 infection, we analysed the four above-mentioned *DEFB1* functional polymorphisms in 101 HIV-1 positive mothers and 331 infants born to HIV-1-positive mothers from Zambia with the aim of investigating their potential impact in the susceptibility to HIV-1 perinatal infection.

## Material and Methods

### Study population

The Zambia Exclusive Breastfeeding Study (ZEBS, Lusaka Zambia, [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00310726) Identifier: NCT00310726) population recruited for this study was previously analysed in another work by Segat et al. [14]: briefly the ZEBS was a randomized clinical trial that investigated if exclusive breastfeeding up to 4 months could reduce the risk of HIV-1 transmission respect to longer breastfeeding through a median of 16 months. Nine hundred and fifty-eight HIV-1 positive women were enrolled during pregnancy at two prenatal care clinics (May 2001 to September 2004), and they were followed to delivery and 24 months post partum with their infants who were tested regularly for HIV. All women were counseled to breastfeed to at least 4 months, then, half of the women were randomized to stop all breastfeeding and the other half to continue breastfeeding for as long as they usually would. Detailed information is provided in table supplementary 1.

For the current genetic analysis 331 infants were selected: 85 were HIV-1 infected (designed as HIV+): 22 (6.9%) had intrauterine MTCT (IU - defined as a positive polymerase chain reaction (PCR) result within 2 days of birth), 25 (7.5%) had intrapartum MTCT (IP - defined as a positive PCR result within 42 days of birth with an earlier negative result) and 38 (14.4%) had postnatal (breastfeeding) MTCT (PP - defined as a positive PCR results older than 42 days with a negative earlier result in a breastfed child). The remainder 246 were HIV-1-exposed uninfected children (designed as HIV-). The samples of 101 available HIV-1 positive mothers (mean age 26 years, range 18–45) of these children were selected and included in the genotyping analysis: 26 of these transmitted the HIV-1 infection to their newborns (designed as TR): 26.9% (7/26) were IU transmitted MTCT, 30.8% (8/26) were IP transmitted, and 42.3% (11/26) were PP transmitted via breastfeeding; 75 mothers did not transmit HIV-1 to their infants (designed as NTR). The numbers of enrolled children and mother is different since a subset of 331 out of 632 infants and 101 mothers out of 958 recruited in the trial had available dried blood spot specimen useful for DNA extraction and subsequent genotyping.

All women provided written informed consent for participating in the study. All the study experiments and procedures have been performed in accordance with ethical standards of the 1975 Declaration of Helsinki (7<sup>th</sup> revision, 2013) and the ethical committee of IRCCS Burlo Garofolo approved the study (protocol L-1106, 1 May 2010).

### DEFB1 genotyping

DNA extraction was performed from dried blood spots as described in Segat et al. [14]. The four polymorphisms at *DEFB1* gene were detected using TaqMan SNPs genotyping assays and TaqMan® GTXpress™ Master Mix on the ABI7900HT Real Time PCR platform (Applied Biosystems - Life Technologies, Carlsbad, California, U.S.A.), following manufacturer instructions: *DEFB1* 5'UTR -52G>A (rs1799946), -44C>G (rs1800972), -20G>A (rs11362) and 3'UTR c.\*87A>G (rs1800971) polymorphisms using respectively C\_\_11636795\_20, C\_\_11636794\_10, C\_\_11636793\_20 and C\_\_8845559\_10 assays.

### Statistical analysis

*DEFB1* allele and genotype frequencies were calculated by direct counting, while haplotype frequencies and linkage disequilibrium were computed using the Arlequin software version 3.5.1.2 [15].

Nonparametric Wilcoxon rank sum test with continuity correction were used to compare continuous variables. Fisher's exact test was used for pairwise comparison of allele, genotype and haplotype frequencies. Logistic regression and Wald's test were conducted to examine the association between polymorphisms genotypes and the risk of HIV-1 MTCT. The statistical tests were performed with the free software R version 3.1.3 [16]. P-value for linkage disequilibrium analysis was calculated using the permutation test with the EM algorithm, on Arlequin [15], whereas D' and r<sup>2</sup> measures were computed with SNPstat [17]. Post-hoc power calculations were performed with G\*Power software version 3.1.9.2 using post-hoc calculation using Fisher's exact test [18].

## Results

HIV-1 MTCT status significantly correlated with maternal CD4 cells count and plasma viral load (Wilcoxon rank sum test with continuity correction  $p=3.544e-08$  and  $p=2.35e-13$  respectively) (table supplementary 1).

*DEFB1* polymorphisms at position  $-52G>A$ ,  $-44C>G$  and  $-20G>A$  were in Hardy Weinberg equilibrium (HWE) in all groups (both of mothers and children) with the exception of the  $-44C>G$  variation in HIV- children group (table 1, 2 and supplementary table 2). The polymorphisms were in linkage disequilibrium in the children but not in the mothers ( $D'>0.51$ ,  $r^2>0.01$ ,  $p<0.04$  and  $D'>0.645$ ,  $r^2>0.02$ ,  $p<0.07$  respectively) and combined to form three major haplotypes, namely ACGA, GCAA, ACGG and other minor haplotypes (with frequency  $<0.05$ ).

Analysing *DEFB1* polymorphisms' allele and genotype frequency distribution no statistical significant differences were observed between HIV+ and HIV- children, also when stratifying for HIV-1 routes of MTCT (table 1, table 2). An exception was the c.\*87 G allele, more frequent among IU HIV+ and associated with increased risk of IU HIV-1 MTCT ( $p=0.02$ , OR=2.09, CI=1.05–4.10, power=0.57; table 2).

When *DEFB1* haplotypes were considered, the GCGA haplotype was significantly more frequent among HIV- children than ACGA more represented in HIV+ and associated with protection towards HIV-1 infection ( $p=0.002$ ; OR=0.18; CI=0.03–0.61; power: 0.93; table 1). When children were stratified according to HIV-1 route of MTCT the ACGG haplotype was more represented among HIV- respect to the ACGA haplotype, more frequent among IP HIV+, and associated with a protection towards IP HIV-1 MTCT ( $p=0.006$  OR= 0.23; CI=0.06–0.70; power: 0.80 table 2).

No statistical significant association was detected between maternal *DEFB1* polymorphisms and the risk of HIV-1 MTCT, comparing NTR and TR mothers (table supplementary 1).

Finally no association was found between the maternal *DEFB1* polymorphisms' genotypes and maternal plasma viral load (data not shown).

The mothers and children data were also stratified based on maternal CD4 cells count and plasma viral load (CD4+cells count: cut off=350 cells/mm<sup>3</sup>; mothers group (n=101): low=17–347 cells/mm<sup>3</sup>, high=350–925 cells/mm<sup>3</sup>; children's mothers (n=331): low=17–349 cells/mm<sup>3</sup>, high=350–1207 cells/mm<sup>3</sup>; plasma viral load cut off=50000 copies/ml; mothers group (n=101): low=399–48180 copies/ml, high=50800–75001 copies/ml; children's mothers (n=331): low=399–49748 copies/ml, high=50291–75001 copies/ml. *DEFB1* polymorphisms frequencies were not significantly different comparing HIV+ and HIV- children and also between TR and NTR mothers (table supplementary 3 and 4 respectively).

## Discussion

In our study we tested the possible association between functional variations at *DEFB1* gene and susceptibility to HIV-1 vertical transmission in mothers and children from Zambia:

specifically we analysed the frequency distributions of four polymorphisms within *DEFB1* gene comparing TR and NTR mothers and HIV-1 positive and negative children.

*DEFB1* c.\*87 A allele associated with decreased susceptibility towards IU HIV-1 MTCT; additionally considering *DEFB1* haplotypes, the GCGA associated with protection towards acquiring HIV-1 MTCT, moreover when the children were stratified according to the route of virus MTCT, the ACGG haplotypes were correlated with decreased IP HIV-1 MTCT susceptibility.

Other previous works showed associations between *DEFB1* polymorphisms and HIV-1 infection in other ethnic groups. In Italians (European Caucasian) the increased HIV-1 infection susceptibility was associated with -44 C/C genotype [19, 20], with -52 A allele [6] and with -52A/-44C haplotype [6] among children. Moreover, the maternal -52G/G genotype and 52G/-44G haplotype were correlated with protection against HIV-1 MTCT [6]. Instead, in Brazilians children the HIV-1 infection susceptibility was associated with -52 A/A and -20 G/G genotype [10], although another work by Segat et al. did not highlight any statistically significant associations [21].

Another study investigated the role of the 5'UTR *DEFB1* polymorphisms in seropositive mother and their infants comparing them with healthy women and their newborns in a population from a Colombia, but no statistically significant different polymorphism frequencies were observed between the two groups [9].

The differences between our findings respect to the previous studies cited above could be explained based upon the different ethnic origin of the population analysed, and considering the fact that in some studies the comparison has been conducted between healthy subjects and HIV-1 infected individuals and not between exposed un-infected and infected subjects; furthermore only our study considered the virus route of transmission, while the others just reported general susceptibility to HIV-1 MTCT. Instead, for the 3'UTR c.\*87A>G polymorphism this was the first study that considered this genetic variant in the context of HIV-1 infection and reported its association with the risk of MTCT.

Beta defensins are important mediators of innate mucosal defence against microbial infection and are also known for their antiviral activities [22]. There are controversial reports regarding *DEFB1* expression in various fluid tissues or cell lines [11, 12, 23, 24, 25], nevertheless hBD-1 is constitutively expressed at the mucosa surface [22] and, very important for HIV-1 MTCT, in the placenta [9]. On the other hand, recent evidences suggested that hBD-1 could be also induced by virus infection *in vitro* and *in vivo* [26], and also in conventional monocytes from HIV-1 infected patients in the acute phase but not in the chronic stage [27]

Our study indicated that the four *DEFB1* polymorphisms could be involved in the HIV-1 infection susceptibility, suggesting also an additive and cooperative effect: it is possible to speculate that the *DEFB1* c.\*87 G allele genotype and *DEFB1* ACGA haplotype, more frequent among HIV+ children might decrease mRNA *DEFB1* expression, consequently diminishing hBD-1 levels, thus leading to an increased risk of acquiring HIV-1 infection. Indeed, a possible explanation of the 5'UTR polymorphisms haplotypes effect as a post-

transcriptional regulation was suggested: haplotypes could impact on RNA folding and so on its expression as suggested by previous works [23, 28]. Moreover, our results were supported by our previous research [24], where the A/G genotype and *DEFB1* ACGA haplotype were correlated with low concentration of hBD-1 in saliva, although the samples were Italian healthy controls.

We are aware of a limitation of our study since the lack of biological samples other than dried blood spots used for DNA extraction, didn't allow us to quantify hBD-1 protein to validate our hypothesis.

In our study *DEFB1* polymorphisms were not correlated with maternal viral load or CD4 cells count, however former works evidenced that -52 G/G genotype was correlated with low levels of HIV-1 RNA in breast milk of Mozambican women [29]. Moreover, -52 G/G genotype and -44C/G genotype were associated with low plasma HIV-1 RNA in Italian women [6]. The difference could be due to different states of disease progression not specified in these studies.

Despite the importance of subject's genetic background, other major factors are supposed to be involved in the susceptibility to the HIV-1 infection such as maternal viral load, virus subtypes and advancement of immune deficiency status [30].

In agreement with previous research, in our study HIV-1 MTCT was associated with low maternal CD4 cells count and high plasma viral load. Garcia et al. found high HIV-1 RNA plasma levels associated with a significant risk of HIV-1 MTCT [31], similarly in population maternal viral loads were significantly higher in transmitters than in non-transmitters. Moreover, low maternal CD4 cells count correlated with an increased risk of HIV-1 MTCT and this finding was in agreement with previous studies [32].

In spite of our positive findings, taken into account some deviations from HWE, probably due to the low number of subjects present in some groups, and the medium value of the power analysis, further studies should be necessary to clarify the role of *DEFB1* gene polymorphisms in the multifactorial trait HIV-1 MTCT, since we just analysed the genome component of our samples not being available any biological material other than dried blood spot, for the functional validation (i.e. ELISA quantification of hBD1) of the associations observed, although as mentioned above, our previous results [24] supported our current data.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

This work has been supported by RC08/17 grant from IRCCS Burlo Garofolo Trieste / Ministry of Health (Italy). This study was supported in part by grants from the *Eunice Kennedy Shriver*, National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) (HD39611, HD40777, HD57617).

VP was recipient of fellowship from IRCCS Burlo Garofolo.



## References

1. UNAIDS. Global AIDS Update 2016, <http://www.unaids.org>. 2016.
2. Singh KK, Spector SA. Host genetic determinants of human immunodeficiency virus infection and disease progression in children. *Pediatr Res*. 2009;65:55R–63R.
3. Carrington M, Bashirova AA, McLaren PJ. On stand by: host genetics of HIV control. *AIDS*. 2013;27:2831–9. [PubMed: 25119688]
4. Liu L, Zhao C, Heng HH, Ganz T. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. *Genomics*. 1997;43:316–20. [PubMed: 9268634]
5. Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J, Krzyzewski J, Zwierzchowski L, Bagnicka E. Defensins: natural component of human innate immunity. *Hum Immunol*. 2013;74:1069–79. [PubMed: 23756165]
6. Ricci E, Malacrida S, Zanchetta M, Montagna M, Giaquinto C, De Rossi A. Role of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. *J Acquir Immune Defic Syndr*. 2009;51:13–9. [PubMed: 19390326]
7. Estrada-Aguirre JA, Osuna-Ramirez I, Prado Montes de Oca E, Ochoa-Ramirez LA, Ramirez M, Magallon-Zazueta LG, Gonzalez-Beltran MS, Cazarez-Salazar SG, Rangel-Villalobos H, Velarde-Felix JS. DEFB1 5'UTR polymorphisms modulate the risk of HIV-1 infection in Mexican women. *Curr HIV Res*. 2014;12:220–6. [PubMed: 25001249]
8. Freguja R, Gianesin K, Del Bianco P, Malacrida S, Rampon O, Zanchetta M, Giaquinto C, De Rossi A. Polymorphisms of innate immunity genes influence disease progression in HIV-1-infected children. *AIDS*. 2012;26:765–8. [PubMed: 22269973]
9. Aguilar-Jimenez W, Zapata W, Rugeles MT. Differential expression of human beta defensins in placenta and detection of allelic variants in the DEFB1 gene from HIV-1 positive mothers. *Biomedica*. 2011;31:44–54. [PubMed: 22159483]
10. Milanese M, Segat L, Pontillo A, Arraes LC, de Lima Filho JL, Crovella S. DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children. *AIDS*. 2006;20:1673–5. [PubMed: 16868452]
11. Milanese M, Segat L, Crovella S. Transcriptional effect of DEFB1 gene 5' untranslated region polymorphisms. *Cancer Res*. 2007;67:5997; author reply [PubMed: 17575171]
12. Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, He J, Ho SM, Svoboda P, Pohl J, Marshall FF, Petros JA. Human beta-defensin-1, a potential chromosome 8p tumor suppressor: control of transcription and induction of apoptosis in renal cell carcinoma. *Cancer Res*. 2006;66:8542–9. [PubMed: 16951166]
13. Flores Saiffe Farias A, Jaime Herrera Lopez E, Moreno Vazquez CJ, Li W, Prado Montes de Oca E. Predicting functional regulatory SNPs in the human antimicrobial peptide genes DEFB1 and CAMP in tuberculosis and HIV/AIDS. *Comput Biol Chem*. 2015;59 Pt A:117–25. [PubMed: 26447748]
14. Segat L, Zupin L, Kim HY, Catamo E, Thea DM, Kankasa C, Aldrovandi GM, Kuhn L, Crovella S. HLA-G 14 bp deletion/insertion polymorphism and mother-to-child transmission of HIV. *Tissue Antigens*. 2014;83:161–7. [PubMed: 24571474]
15. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. *Mol Ecol Resour*. 2010;10:564–7. [PubMed: 21565059]
16. RcoreTeam. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/2015>.
17. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. *Bioinformatics*. 2006;22:1928–9. [PubMed: 16720584]
18. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 2007;39:175–91. [PubMed: 17695343]

19. Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S. A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. *AIDS*. 2004;18:1598–600. [PubMed: 15238780]
20. Segat L, Milanese M, Boniotto M, Crovella S, Bernardon M, Costantini M, Alberico S, Italian Group SHIViO, Gynecology. DEFB-1 genetic polymorphism screening in HIV-1 positive pregnant women and their children. *J Matern Fetal Neonatal Med*. 2006;19:13–6. [PubMed: 16572527]
21. Segat L, Brandao LA, Guimaraes RL, Crovella S. Are defensin beta 1 gene polymorphisms associated with HIV infection and virus replication? *AIDS*. 2009;23:647–9; author reply 9–50. [PubMed: 19516112]
22. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC. Human defensins. *J Mol Med (Berl)*. 2005;83:587–95. [PubMed: 15821901]
23. Kalus AA, Fredericks LP, Hacker BM, Dommisch H, Presland RB, Kimball JR, Dale BA. Association of a genetic polymorphism (–44 C/G SNP) in the human DEFB1 gene with expression and inducibility of multiple beta-defensins in gingival keratinocytes. *BMC Oral Health*. 2009;9:21. [PubMed: 19712472]
24. Polesello V, Zupin L, Di Lenarda R, Biasotto M, Ottaviani G, Gobbo M, Cecco L, Alberi G, Pozzato G, Crovella S, Segat L. Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration. *Arch Oral Biol*. 2015;60:1054–8. [PubMed: 25939140]
25. Nurjadi D, Herrmann E, Hinderberger I, Zanger P. Impaired beta-defensin expression in human skin links DEFB1 promoter polymorphisms with persistent *Staphylococcus aureus* nasal carriage. *J Infect Dis*. 2013;207:666–74. [PubMed: 23204181]
26. Ryan LK, Diamond G. Modulation of Human beta-Defensin-1 Production by Viruses. *Viruses*. 2017;9.
27. Corleis B, Lisanti AC, Korner C, Schiff AE, Rosenberg ES, Allen TM, Altfeld M, Kwon DS. Early type I Interferon response induces upregulation of human beta-defensin 1 during acute HIV-1 infection. *PLoS One*. 2017;12:e0173161. [PubMed: 28253319]
28. Naslavsky MS, Crovella S, Lima Filho JL, Rocha CR. The sound of silence: human beta-defensin-1 gene untranslated SNPs change the predicted mRNA secondary structure in a length-dependent manner. *Immunol Lett*. 2010;129:53–5. [PubMed: 20060856]
29. Baroncelli S, Ricci E, Andreotti M, Guidotti G, Germano P, Marazzi MC, Vella S, Palombi L, De Rossi A, Giuliano M. Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. *AIDS*. 2008;22:1515–7. [PubMed: 18614876]
30. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. *Lancet*. 1992;339:1007–12. [PubMed: 1349050]
31. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moyer J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. *N Engl J Med*. 1999;341:394–402. [PubMed: 10432324]
32. Kuhn L, Coutoudis A, Trabattoni D, Archary D, Rossi T, Segat L, Clerici M, Crovella S. Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers. *Am J Clin Nutr*. 2006;84:610–5. [PubMed: 16960176]



**Table 1:**

analysis of HIV-1 MTCT according to infant *DEFBI* polymorphisms allele, genotype and haplotype frequencies comparing HIV-1 infected (HIV+) and HIV-1 exposed but not infected (HIV-) children.

CHILDREN	HIV+ <sup>a</sup>	HIV- <sup>b</sup>	HIV+ <sup>a</sup> vs. HIV- <sup>b</sup>
	n=85	n=246	p-value, O.R. <sup>c</sup> , 95% C.I. <sup>d</sup>
<b>DEFBI</b>			
<b>-52A&gt;G rs1799946</b>			
A	0.61 (103)	0.60 (293)	reference
G	0.39 (67)	0.40 (199)	p=0.86; OR <sup>c</sup> =0.96; CI <sup>d</sup> =0.66–1.39
A/A	0.36 (31)	0.36 (89)	reference
G/A	0.48 (41)	0.47 (115)	p=1.00; OR <sup>c</sup> =1.02; CI <sup>d</sup> =0.57–1.83
G/G	0.15 (13)	0.17 (42)	p=0.85; OR <sup>c</sup> =0.89; CI <sup>d</sup> =0.38–1.97
HWE <sup>e</sup>	$\chi^2=0.01$ ; p=0.93	$\chi^2=0.22$ ; p=0.64	
<b>-44C&gt;G rs1800972</b>			
C	0.95 (161)	0.94 (462)	reference
G	0.05 (9)	0.06 (30)	p=0.85; OR <sup>c</sup> =0.86 CI <sup>d</sup> =0.35–1.91
C/C	0.89 (76)	0.89 (219)	reference
C/G	0.11 (9)	0.10 (24)	p=0.83; OR <sup>c</sup> =1.08; CI <sup>d</sup> =0.42–2.54
G/G	0.00 (0)	0.01 (3)	Not calculable
HWE <sup>e</sup>	$\chi^2=0.27$ ; p=0.61	$\chi^2=5.39$ ; p=0.02	
<b>-20A&gt;G rs11362</b>			
G	0.69 (117)	0.71 (348)	reference
A	0.31 (53)	0.29 (144)	p=0.63; OR <sup>c</sup> =1.09; CI <sup>d</sup> =0.73–1.62
G/G	0.48 (41)	0.51 (125)	reference
G/A	0.41 (35)	0.40 (98)	p=.079; OR <sup>c</sup> =1.09 CI <sup>d</sup> =0.62–1.90
A/A	0.11 (9)	0.09 (23)	p=0.66; OR <sup>c</sup> =1.19; CI <sup>d</sup> =0.45–2.94
HWE <sup>e</sup>	$\chi^2=0.14$ ; p=0.71	$\chi^2=0.35$ ; p=0.55	
<b>c.*87A&gt;G rs1800971</b>			
A	0.70 (119)	0.73 (361)	reference
G	0.30 (51)	0.27 (131)	p=0.43; OR <sup>c</sup> =1.18; CI <sup>d</sup> =0.79–1.76
A/A	0.47 (40)	0.53 (131)	reference
G/A	0.46 (39)	0.40 (99)	p=0.36; OR <sup>c</sup> =1.29; CI <sup>d</sup> =0.75–2.22
G/G	0.07 (6)	0.06 (16)	p=0.79; OR <sup>c</sup> =1.23; CI <sup>d</sup> =0.37–3.58

CHILDREN	HIV+ <sup>a</sup>	HIV- <sup>b</sup>	HIV+ <sup>a</sup> vs. HIV- <sup>b</sup>
HWE <sup>e</sup>	$\chi^2=0.73$ ; p=0.39	$\chi^2=0.22$ ; p=0.64	
<b>Haplotypes</b>			
ACGA	0.33 (56)	0.30 (147)	reference
GCAA	0.25 (43)	0.25 (121)	p=0.81; OR <sup>c</sup> =0.93; CI <sup>d</sup> =0.57–1.52
ACGG	0.22 (38)	0.24 (117)	p=0.55; OR <sup>c</sup> =0.85 CI <sup>d</sup> =0.51–1.41
GCGA	0.02 (3)	0.09 (43)	p=0.002; OR <sup>c</sup> =0.18; CI <sup>d</sup> =0.03–0.61
others	0.18 (30)	0.13 (64)	p=0.49; OR <sup>c</sup> =1.23; CI <sup>d</sup> =0.69–2.16

<sup>a</sup>HIV+ = HIV-1 infected children

<sup>b</sup>HIV- = HIV-1 exposed but not infected children

<sup>c</sup>OR= odds ratio

<sup>d</sup>CI= confidence interval

<sup>e</sup>HWE = Hardy Weinberg equilibrium

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2:**

*DEFBI* polymorphisms allele, genotype frequencies (and counts) in HIV-1 exposed but not infected children (HIV-) and HIV-1 infected children stratifying for timing of HIV-1 MTCT in intruterine (IU), intrapartum (IP) and postpartum (PP) groups.

CHILDREN	IU <sup>a</sup>	IP <sup>b</sup>	PP <sup>c</sup>	HIV- <sup>d</sup>	IU <sup>a</sup> vs HIV- <sup>d</sup>	IP <sup>b</sup> vs HIV- <sup>d</sup>	PP <sup>c</sup> vs HIV- <sup>d</sup>
	n=22	n=25	n=38	n=246	p-value, O.R. <sup>e</sup> , 95% C.I. <sup>f</sup>	p-value, O.R. <sup>e</sup> , 95% C.I. <sup>f</sup>	p-value, O.R. <sup>e</sup> , 95% C.I. <sup>f</sup>
<i>DEFBI</i>							
-52A>G rs1799946							
A	0.57 (25)	0.56 (28)	0.66 (50)	0.60 (293)	reference	reference	reference
G	0.43 (19)	0.44 (22)	0.34 (26)	0.40 (199)	p=0.75; OR <sup>e</sup> =1.12; CI <sup>f</sup> =0.57-2.18	p=0.65; OR <sup>e</sup> =1.16; CI <sup>f</sup> =0.61-2.16	p=0.38; OR <sup>e</sup> =0.77; CI <sup>f</sup> =0.44-1.30
A/A	0.41 (9)	0.28 (7)	0.39 (15)	0.36 (89)	reference	reference	reference
G/A	0.32 (7)	0.56 (14)	0.53 (20)	0.47 (115)	p=0.43; OR <sup>e</sup> =0.60; CI <sup>f</sup> =0.18-1.90	p=0.49; OR <sup>e</sup> =1.54; CI <sup>f</sup> =0.55-4.72	p=1.00; OR <sup>e</sup> =1.03; CI <sup>f</sup> =0.47-2.30
G/G	0.27 (6)	0.16 (4)	0.08 (3)	0.17 (42)	p=0.57; OR <sup>e</sup> =1.41; CI <sup>f</sup> =0.39-4.77	p=0.75; OR <sup>e</sup> =1.21; CI <sup>f</sup> =0.25-5.07	p=0.27; OR <sup>e</sup> =0.43; CI <sup>f</sup> =0.07-1.62
HWE <sup>g</sup>	$\chi^2=2.72$ p=0.10	$\chi^2=0.46$ p=0.50	$\chi^2=1.09$ p=0.30	$\chi^2=0.22$ p=0.64			
-44C>G rs1800972							
C	0.93 (41)	0.92 (46)	0.97 (74)	0.94 (462)	reference	reference	reference
G	0.07 (3)	0.08 (4)	0.03 (2)	0.06 (30)	p=0.75; OR <sup>e</sup> =1.13; CI <sup>f</sup> =0.21-3.87	p=0.54; OR <sup>e</sup> =1.34; CI <sup>f</sup> =0.33-4.04	p=0.29; OR <sup>e</sup> =0.42; CI <sup>f</sup> =0.05-1.70
C/C	0.86 (19)	0.84 (21)	0.95 (36)	0.89 (219)	reference	reference	reference
C/G	0.14 (3)	0.16 (4)	0.05 (2)	0.10 (24)	p=0.48; OR <sup>e</sup> =1.44; CI <sup>f</sup> =0.25-5.44	p=0.31; OR <sup>e</sup> =1.73; CI <sup>f</sup> =0.40-5.77	p=0.55; OR <sup>e</sup> =0.51; CI <sup>f</sup> =0.06-2.20
G/G	0.00 (0)	0.00 (0)	0.00 (0)	0.01 (3)	p=1.00; OR <sup>e</sup> =0.00; CI <sup>f</sup> =0.00-29.21	p=1.00; OR <sup>e</sup> =0.00; CI <sup>f</sup> =0.00-26.33	p=1.00; OR <sup>e</sup> =0.00; CI <sup>f</sup> =0.00-15.13
HWE <sup>g</sup>	$\chi^2=0.12$ p=0.73	$\chi^2=0.19$ p=0.66	$\chi^2=0.03$ p=0.87	$\chi^2=5.39$ p=0.02			
-20A>G rs11362							
G	0.70 (31)	0.70 (35)	0.67 (51)	0.71 (348)	reference	reference	reference

CHILDREN	IU <sup>a</sup>	IP <sup>b</sup>	PP <sup>c</sup>	HIV-d	IU <sup>a</sup> vs HIV-d	IP <sup>b</sup> vs HIV-d	PP <sup>c</sup> vs HIV-d
A	0.30 (13)	0.30 (15)	0.33 (25)	0.29 (144)	p=1.00; OR <sup>e</sup> =1.01; CI <sup>f</sup> =0.47-2.06	p=1.00; OR <sup>e</sup> =1.04; CI <sup>f</sup> =0.51-2.02	p=0.50; OR <sup>e</sup> =1.18; CI <sup>f</sup> =0.68-2.03
G/G	0.59 (13)	0.48 (12)	0.42 (16)	0.51 (125)	reference	reference	reference
G/A	0.23 (5)	0.44 (11)	0.50 (19)	0.40 (98)	p=0.22; OR <sup>e</sup> =0.49; CI <sup>f</sup> =0.13-1.53	p=0.82; OR <sup>e</sup> =1.17; CI <sup>f</sup> =0.45-3.03	p=0.27; OR <sup>e</sup> =1.51; CI <sup>f</sup> =0.69-3.32
A/A	0.18 (4)	0.08 (2)	0.08 (3)	0.09 (23)	p=0.48; OR <sup>e</sup> =1.67; CI <sup>f</sup> =0.36-6.05	p=1.00; OR <sup>e</sup> =0.91; CI <sup>f</sup> =0.09-4.50	p=1.00; OR <sup>e</sup> =1.02; CI <sup>f</sup> =0.18-4.00
HWE <sup>g</sup>	$\chi^2=4.54$ p=0.03	$\chi^2=0.06$ p=0.81	$\chi^2=0.67$ p=0.41	$\chi^2=0.35$ p=0.55			
c:*87A>G rs1800971							
A	0.57 (25)	0.82 (41)	0.70 (53)	0.73 (361)	reference	reference	reference
G	0.43 (19)	0.18 (9)	0.30 (23)	0.27 (131)	p=0.02; OR <sup>e</sup> =2.09; CI <sup>f</sup> =1.05-4.10	p=0.23; OR <sup>e</sup> =0.60; CI <sup>f</sup> =0.25-1.31	p=0.49; OR <sup>e</sup> =1.20; CI <sup>f</sup> =0.67-2.08
A/A	0.27 (6)	0.64 (16)	0.47 (18)	0.53 (131)	reference	reference	reference
G/A	0.59 (13)	0.36 (9)	0.45 (17)	0.40 (99)	p=0.05; OR <sup>e</sup> =2.85; CI <sup>f</sup> =0.97-9.49	p=0.53; OR <sup>e</sup> =0.74; CI <sup>f</sup> =0.28-1.88	p=0.59; OR <sup>e</sup> =1.25; CI <sup>f</sup> =0.57-2.71
G/G	0.14 (3)	0.00 (0)	0.08 (3)	0.06 (16)	p=0.08; OR <sup>e</sup> =4.04; CI <sup>f</sup> =0.60-21.25	p=0.37; OR <sup>e</sup> =0.00; CI <sup>f</sup> =0.00-2.39	p=0.81; OR <sup>e</sup> =1.36; CI <sup>f</sup> =0.23-5.48
HWE <sup>g</sup>	$\chi^2=0.92$ p=0.34	$\chi^2=1.20$ p=0.27	$\chi^2=0.14$ p=0.71	$\chi^2=0.22$ p=0.64			
<b>Haplotypes</b>							
ACGA	0.23 (10)	0.44 (22)	0.32 (24)	0.30 (147)	reference	reference	reference
GCAA	0.25 (11)	0.26 (13)	0.25 (19)	0.25 (121)	p=0.65; OR <sup>e</sup> =1.34; CI <sup>f</sup> =0.50-3.64	p=0.47; OR <sup>e</sup> =0.72; CI <sup>f</sup> =0.32-1.56	p=1.00; OR <sup>e</sup> =0.96; CI <sup>f</sup> =0.47-1.93
ACGG	0.32 (14)	0.08 (4)	0.26 (20)	0.24 (117)	p=0.20; OR <sup>e</sup> =1.76; CI <sup>f</sup> =0.70-4.59	p=0.006; OR <sup>e</sup> =0.23; CI <sup>f</sup> =0.06-0.70	p=1.00; OR <sup>e</sup> =1.05; CI <sup>f</sup> =0.52-2.09
GCGA	0.00 (0)	0.02 (1)	0.03 (2)	0.09 (43)	p=0.12; OR <sup>e</sup> =0.00; CI <sup>f</sup> =0.00-1.60	p=0.05; OR <sup>e</sup> =0.16; CI <sup>f</sup> =0.00-1.02	p=0.11; OR <sup>e</sup> =0.29; CI <sup>f</sup> =0.03-1.23
others	0.20 (9)	0.20 (10)	0.14 (11)	0.13 (64)	p=0.13; OR <sup>e</sup> =2.06; CI <sup>f</sup> =0.70-5.95	p=1.00; OR <sup>e</sup> =1.04; CI <sup>f</sup> =0.42-2.46	p=1.00; OR <sup>e</sup> =1.05; CI <sup>f</sup> =0.44-2.39

<sup>a</sup>IU = intravaginal HIV-1 mother to child transmission

<sup>b</sup>IP = intrapartum HIV-1 mother to child transmission

pp = postpartum HIV-1 mother to child transmission  
HIV<sub>p</sub> = HIV-1 exposed but not infected children  
OR = odds ratio  
CI = confidence interval  
HWE = Hardy Weinberg equilibrium

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript